3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gastrointestinal
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Carcinoma, Non-Small-Cell Lung
2
Squamous Cell Carcinoma of Head and Neck
1
Solitary Fibrous Tumors
1
Sarcoma
1
Ovarian Neoplasms
1
Lung Neoplasms
1
Liposarcoma
1
Histiocytoma, Malignant Fibrous
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Dermatofibrosarcoma
1
Colorectal Neoplasms
1
Interventions
Specimen Handling
10
Biopsy
9
Magnetic Resonance Spectroscopy
8
pembrolizumab
6
Cyclophosphamide
6
X-Rays
5
Phantoms, Imaging
5
Doxorubicin
5
Nuclear Medicine Department, Hospital
4
fludarabine
3
Radiation
3
Irinotecan
3
ulixertinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
palbociclib
2
liposomal doxorubicin
2
larotrectinib
2
ivosidenib
2
fludarabine phosphate
2
ensartinib
2
atezolizumab
2
anlotinib
2
Temozolomide
2
Surveys and Questionnaires
2
Radiotherapy
2
Ifosfamide
2
Fluorodeoxyglucose F18
2
Carboplatin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma
×
Histamine H2 Antagonists
×
30 days
×
Clear all
NCT06789172
2026-05-22
INVOKE
Epkin
Phase 1
Recruiting
166 enrolled